Biotechnology company Nucleome Therapeutics has signed a deal for 20,000 sq ft at Mission Street and BGO’s 65,000 sq ft Inventa scheme in Oxford.
Nucleome, originally a spinout from Oxford University, aims to address traditional drug discovery failure rates. The firm will relocate from its existing headquarters at the Oxford Science Park.
While Inventa is filling, Mission Street plans to begin work in September on its new West End neighbour, Fabrica. It will add a further 183,000 sq ft of labs and offices.
Artem Korolev, founder and chief executive of Mission Street, said: “Following extensive collaboration between our teams in designing and delivering Nucleome’s facility, we are excited to welcome them to Inventa for the next chapter of their growth. We look forward to building a long-term partnership with them and delivering a world class urban innovation district across Inventa, Fabrica and the wider West End.”
Stephen Harrison, chief scientific officer of Nucleome Therapeutics, said: “Nucleome’s expansion, driven by the significant progress in identifying new drug candidates, has resulted in a need for larger office and lab space.
“We chose Inventa because of its central location, and Mission Street’s reputation for designing buildings that thoroughly accommodate the needs of life science companies. We are looking forward to being part of this exciting new science and innovation hub in central Oxford.”
CBRE and Bidwells advised on the leasing.
© Thames Tap (powered by ukpropertyforums.com).
Sign up to receive our weekly free journal, The Forum here.
My site Webemail24 covers a lot of topics about Apartments and I thought we could greatly benefit from each other. Awesome posts by the way!
Your posts stand out from other sites I’ve read stuff from. Keep doing what you’re doing! Here, take a look at mine Seoranko for content about about Search Engine Optimization.